Latest stories on IVA
Inventiva: Significant Upside Potential Ahead Of Pivotal Liver Disease Readout
Seeking Alpha64 · neutralanalyst
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
MarketBeat67 · bullishanalyst
Inventiva spotlights lanifibranor’s pan-PPAR rationale with three AASLD 2026 abstracts as Phase 3 NATiV3 readout nears
October 7, 2026
MarketChameleon67 · bullishproduct/pr
Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026
Business Insider56 · neutralproduct/pr
Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026
GlobeNewswire63 · neutralproduct/pr
Inventiva présentera plusieurs abstracts scientifiques lors de l’AASLD The Liver Meeting® 2026
GlobeNewswire56 · neutralproduct/pr
Inventiva price target raised to $18 from $13 at Truist
The Fly61 · neutralanalyst
Inventiva (IVA) Q2 2026 Earnings Call Transcript
The Motley Fool63 · neutralearnings
Inventiva price target raised to $21 from $20 at Canaccord
The Fly61 · neutralanalyst
Truist reiterates Buy on Inventiva stock ahead of phase 3 data
Investing.com Analyst Ratings63 · neutralanalyst
Inventiva S.A. (IVA) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Inventiva S.A. 2026 Q2 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Options Volatility and Implied Earnings Moves Today, September 28, 2026
TipRanks50 · neutralearnings
Inventiva S.A reports 1H results
Seeking Alpha28 · bearishearnings
Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
GlobeNewswire50 · neutralgeneral
Stifel reiterates Buy on Inventiva stock, $15 target on MASH drug
Investing.com Analyst Ratings61 · neutralanalyst
Stifel reiterates Buy on Inventiva stock ahead of trial data
Investing.com Analyst Ratings61 · neutralanalyst
Piper Sandler reiterates Inventiva stock rating on trial confidence
Investing.com Analyst Ratings56 · neutralanalyst
Inventiva S.A. (IVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha56 · neutralgeneral
Inventiva price target raised to $14 from $11 at Guggenheim
The Fly61 · neutralanalyst
Inventiva to Present Multiple Abstracts at Paris MASH 2026
GlobeNewswire63 · neutralproduct/pr
Inventiva Hits Phase 3 Milestone as MASH Drug Lanifibranor Nears Key Readout
TipRanks67 · bullishproduct/pr
Inventiva announces last patient visit in NATiV3 trial
The Fly59 · neutralproduct/pr
Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH
GlobeNewswire63 · neutralproduct/pr
Chris Benecchi Named Inventiva’s New Chief Operating Officer
Yahoo Top56 · neutralgeneral